Corvus Pharmaceuticals, Inc. insider trading

CRVSNASDAQ

$10.90-0.03 (-0.27%)as of Oct 2, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (+54.8%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
Date	Category	Person	Role	Action	Amount	Change in holding

Open market purchase

Open market sell

Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium

Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Unlock quarterly net flow

Key players

PAPeter A. ThompsonDirector10.4838%of company
RARichard A. Miller M.D.President and CEO2.7719%of company
WBWilliam Benton JonesSee Remarks0.2058%of company
RvRichard van den BroekDirector0.1902%of company
DSDavid Scott MooreDirector0.0258%of company
OAOrbimed Advisors LLCDirectorNot reportedof company

AI Activity Analysis

Premium

Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto

Company	Insider / role	Action	ΔOwn	Avg price	Amount
CRVS	David Scott MooreDirector	Open market purchase$250K	Not reported	$11.53	$250K	Jun 11, 2026	Jun 15, 2026
CRVS	Richard A. Miller M.D.President and CEO	Open market purchase$23.2K	+0.1%	$12.01	$23.2K	May 18, 2026	May 20, 2026
CRVS	Richard A. Miller M.D.President and CEO	Open market purchase$60.3K	+0.2%	$12.05	$60.3K	May 18, 2026	May 20, 2026

End of history · 3 transactions